The present invention relates to a container comprising haemoglobin fractions, wherein said container comprising at least two compartments, wherein a first compartment comprises O2Hb (oxyhaemoglobin) and a second compartment comprises MetHb (methaemoglobin), optionally wherein O2Hb is stabilized. The invention also relates to a kit for determining the reliability of a CO-oximetry device, wherein said kit comprises said container and to a method for determining the reliability of a CO-oximetry device using said container.

The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.

The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.

A method of diagnosing and treating insulin resistance at the end of a first phase insulin response to glucose in a mammalian subject is disclosed. The method includes administering an amount of glucose to the mammalian subject capable of producing a first phase insulin response to glucose. At the end of the first phase insulin response to glucose, a serum sample is obtained from the mammalian subject, from which the levels of at least one biomarker for insulin resistance may be measured, from a group including insulin, proinsulin, C-peptide, glucose, and hemoglobin A1c. An analysis of the levels of the biomarkers in the serum samples may be performed to determine if the mammalian subject is insulin dependent. If the mammalian subject is determined to have insulin resistance, treatments for insulin resistance may be prescribed. Prescribed treatments include weight loss, dietary modification, exercise, or drug therapy.

There is provided a urine test device for detecting the presence of one or more compounds in urine. The test device comprises a base portion having a detection portion and a flexible attachment portion. The detection portion displays a change when the presence of any one of one or more compounds is detected in urine. The flexible attachment portion is movable from a first configuration to a second configuration in which the flexible attachment portion is extended to enable attachment to a toilet bowl.

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor assoicated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.

A blood measuring device control method, the device including a sample preparing part that prepares a measurement sample by mixing a blood sample and a reagent, and a measuring part that measures the measurement sample, where the method includes preparing the reagent by mixing a high concentration reagent and pure water; and performing a washing operation by washing sites of the blood measuring device least affecting the measurement results of the measurement sample with pure water, and washing sites of the blood measuring device affecting the measurement results of the measurement sample with the reagent.

A method for counting blood cells in a sample of whole blood. The method comprises the steps of: (a) providing a sample of whole blood; (b) depositing the sample of whole blood onto a slide, e.g., a microscope slide; (c) employing a spreader to create a blood smear; (d) allowing the blood smear to dry on the slide; (e) measuring absorption or reflectance of light attributable to the hemoglobin in the red blood cells in the blood smear on the slide; (f) recording a magnified two-dimensional digital image of the area of analysis identified by the measurement in step (e) as being of suitable thickness for analysis; and (g) collecting, analyzing, and storing data from the magnified two-dimensional digital image.
Optionally, steps of fixing and staining of blood cells on the slide can be employed in the method.

The present invention relates to stem cell-derived mature cardiomyocytes and a cardiovascular disease model using same and, more specifically, to differentiation into mature ventricular cardiomyocytes by culturing stem cells in a medium containing FGF4 and ascorbic acid, and use of the differentiated mature ventricular cardiomyocytes as a cardiovascular disease cell model. The mature ventricular cardiomyocytes, obtained by culturing stem cells in a medium containing FGF4 and ascorbic acid and inducing the differentiation thereof, and cardiovascular disease cell model using same according to the present invention are very useful for screening for cardiovascular disease therapeutic agents and evaluation of the toxicity of new drugs.

The present invention relates to, in part, methods of improved healthcare in female subjects that, for example, rely on menstrual fluid sampling for applying selection biomarkers.